^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alphalex-exatecan (CBX-12)

    i
    Other names: CBX-12
    Associations

    News

    Trials
    Company:
    Cybrexa Therap
    Drug class:
    Topoisomerase I inhibitor
    Related drugs:
    Associations

    News

    Trials
    6d
    CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Metastases
    |
    SLFN11 (Schlafen Family Member 11)
    |
    SLFN11 expression
    |
    alphalex-exatecan (CBX-12)
    4ms
    A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Cybrexa Therapeutics | Trial completion date: Apr 2026 --> Jul 2026 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date
    |
    alphalex-exatecan (CBX-12)
    4ms
    CBX-12-101: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Cybrexa Therapeutics | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: May 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    alphalex-exatecan (CBX-12)
    8ms
    Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (clinicaltrials.gov)
    P1, N=35, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Mar 2025 --> Oct 2026 | Trial primary completion date: Mar 2025 --> Oct 2026
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    RAD51 (RAD51 Homolog A)
    |
    alphalex-exatecan (CBX-12)
    9ms
    A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Cybrexa Therapeutics
    New P2 trial
    |
    alphalex-exatecan (CBX-12)
    11ms
    CBX-12-101: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Cybrexa Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Feb 2024 --> May 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    alphalex-exatecan (CBX-12)
    1year
    Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2023 --> Feb 2024
    Trial initiation date • Metastases
    |
    RAD51 (RAD51 Homolog A)
    |
    alphalex-exatecan (CBX-12)
    1year
    Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Apr 2023 --> Oct 2023
    Trial initiation date • Metastases
    |
    RAD51 (RAD51 Homolog A)
    |
    alphalex-exatecan (CBX-12)
    almost2years
    Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    RAD51 (RAD51 Homolog A)
    |
    alphalex-exatecan (CBX-12)